Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Elongin C pseudogene 35 (ELOCP35) is classified as a pseudogene in the human genome. It is officially named "transcription elongation factor B (SIII), polypeptide 1 pseudogene 35" and also referred to as TCEB1P35. Pseudogenes are segments of DNA that resemble functional genes but are non-coding and generally do not produce functional proteins. There is no evidence that ELOCP35 encodes a functional protein or plays any direct role in biological functions, disease processes, or drug interactions. It is not considered a therapeutic target. The prefix “pseudogene” and all available database entries indicate that ELOCP35 is not a protein-coding gene and does not serve as a receptor, enzyme, or other common drug target class. No literature or recognized biological function, disease role, or drug interaction is associated with ELOCP35, in contrast to its parent gene ELOC, which encodes the functional protein elongin C.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Elongin C pseudogene 35 (ELOCP35).